Zentalis Pharmaceuticals, Inc.
ZNTL
$4.14
-$0.01-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 26.87M | 26.87M | 26.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 26.87M | 26.87M | 26.87M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 26.87M | 26.87M | 26.87M |
| SG&A Expenses | 30.99M | 32.43M | 68.67M | 72.49M | 81.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.95M | 139.72M | 178.25M | 195.94M | 226.19M |
| Operating Income | -140.95M | -139.72M | -151.38M | -169.08M | -199.32M |
| Income Before Tax | -123.57M | -136.62M | -149.52M | -163.02M | -224.15M |
| Income Tax Expenses | 562.00K | 442.00K | -205.00K | -232.00K | 34.00K |
| Earnings from Continuing Operations | -124.13 | -137.06 | -149.32 | -162.78 | -224.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 0.00 | 0.00 | 0.00 |
| Net Income | -124.13M | -137.06M | -149.32M | -162.78M | -224.19M |
| EBIT | -140.95M | -139.72M | -151.38M | -169.08M | -199.32M |
| EBITDA | -140.32M | -138.99M | -150.48M | -168.02M | -198.09M |
| EPS Basic | -1.74 | -1.91 | -2.08 | -2.28 | -3.15 |
| Normalized Basic EPS | -1.07 | -1.03 | -1.17 | -1.29 | -1.64 |
| EPS Diluted | -1.74 | -1.91 | -2.08 | -2.28 | -3.15 |
| Normalized Diluted EPS | -1.07 | -1.03 | -1.17 | -1.29 | -1.64 |
| Average Basic Shares Outstanding | 286.06M | 287.47M | 287.08M | 286.05M | 285.10M |
| Average Diluted Shares Outstanding | 286.06M | 287.47M | 287.08M | 286.05M | 285.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |